Active Nonsegmental Vitiligo, Stable Nonsegmental Vitiligo
Conditions
Brief summary
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Detailed description
Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo (both active and stable vitiligo).
Interventions
DRUGRitlecitinib
50 mg capsule
DRUGPlacebo
Matching capsule
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Double-blind, parallel-group, vehicle controlled.
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants ≥18 years of age at Screening. Adolescents (12 to \<18 years of age) are also eligible for this study, but only if approved by the local IRB/EC and regulatory health authority. Where these approvals have not been granted, only participants ≥18 years of age will be enrolled. Disease Characteristics: 2. Eligible participants must have at both Screening and Baseline: * A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and * BSA involvement 4%-60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet; and * BSA ≥0.5% involvement on the face (face is defined as including the area on the forehead to the original hairline, on the cheek vertically to the jawline, and laterally from the corner of the mouth to the tragus. The face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and * F-VASI ≥0.5 \& T-VASI ≥3; and * Either active or stable disease nonsegmental vitiligo at both Screening and Baseline visits. All participants who do not have the features of active vitiligo (defined below) are required to have stable disease. Active vitiligo is defined as: * Participants will be classified as having active vitiligo based on the presence of at least one active lesion at baseline defined as one of the following: * New/extending lesion(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record): * Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters; * Trichrome lesion(s);Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin; * Koebner phenomenon/phenomena (excluding Type 1 \[history based on isomorphic reaction\]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement. Stable vitiligo is defined as an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) are required to have stable disease. Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA. Other Inclusion Criteria: 3. If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study. 4. Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.
Exclusion criteria
1. Any psychiatric condition including recent or active suicidal ideation or behavior that meets any of the following criteria: * Suicidal ideation associated with actual intent and a method or plan in the past year: "Yes" answers on items 4 or 5 of the C-SSRS administered at the screening visit. * Previous history of suicidal behaviors in the past 5 years: "Yes" answer (for events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS. * For adults, any lifetime history of serious suicidal behavior or recurrent suicidal behavior. For adolescents, any previous lifetime history of suicidal behavior. 2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin: * Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criterion #2 (including, but not limited to, segmental vitiligo and mixed vitiligo). * Currently have active forms of other disorders of pigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation \[melanoma and mycosis fungoides\], post-inflammatory hypopigmentation, pityriasis alba \[minor manifestation of atopic dermatitis\], senile leukoderma \[age-related depigmentation\], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma (all types, including mixed), and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted. * Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or Baseline Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment. * Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions OR leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions. * Have a superficial skin infections within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves. 3. General Infection History: * Having a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1. * Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves. * Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium TB 4. Specific Viral Infection History: * History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster. * Infected with hepatitis B or hepatitis C viruses: all participants will undergo screening for hepatitis B and C for eligibility. * Participants who are positive for HCVAb and HCV RNA will not be eligible for this study. * Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency. 5. Medical Conditions, Other: * Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements. * History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention. * Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating or progressive. * Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease. * Abnormal findings on the Screening chest imaging (eg, chest x-ray) that may increase the risk associated with study participation including, but not limited to, presence of active TB, general infections, cardiomyopathy, or malignancy. Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation. * Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP. * Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. * Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study. Prior/Concomitant Therapy: 6. Have received any of the prohibited treatment regimens specified. Prior/Concurrent Clinical Study Experience: 7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 \[Baseline\] or within 5 half-lives, whichever is longer. Diagnostic Assessments: 8. Any of the following abnormalities in laboratory values at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat: * Renal impairment * Hepatic dysfunction 9. Screening standard 12-lead ECG that demonstrates clinically relevant abnormalities Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities | Baseline through Week 52 | Safety and tolerability of ritlecitinib in participants with nonsegmental vitiligo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| US-Only: Response based on F-VASI75 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline |
| US-Only: Response based on T-VASI50 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| US-Only: Response based on T-VASI75 at 52 weeks | Week 52 | Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
| US-Only: Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| US-Only: Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| US-Only: Patient Global Impression of Severity-Face (PGIS-F) | Week 52 | Proportion of responders based on PGIS-F at 52 weeks |
| US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Week 52 | Proportion of responders based on PGIS-V at 52 weeks |
| Global (Other than US): Response based on F-VASI75 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Global (Other Than US): Response based on T-VASI50 at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Global (Other than US): Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Global (Other than US): Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Global (Other than US): Patient Global Impression of Severity-Face (PGIS-F) | Weeks 24, 36, and 52 | Proportion of responders based on PGIS-F at 24, 36, and 52 weeks |
| Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Weeks 24, 36, and 52 | Proportion of responders based on PGIS-V at 24, 36, and 52 weeks |
| All Countries: Proportion of participants achieving disease stabilization | Baseline through week 52 | The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD compared to placebo |
| Response based on T-VASI50 | Baseline through week 4, week 8, week 12, week 48 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Response based on F-VASI75 | Baseline through week 4, week 8, week 12, week 48 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Response based on T-VASI75 | Baseline through week 4, week 8, week 12, week 24, week 36, week 48 | Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
| Proportion of participants with sustained improvement in T-VASI | Week 36 through week 52 | Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52 |
| Proportion of participants with sustained improvement in F-VASI | Week 36 through week 52 | Defined as maintenance of ≥F-VASI75 from Week 36 to 52 |
| All Countries: Time to rescue medication | Baseline through week 52 | Comparing time to rescue medication curves and difference in probabilities of using rescue medication |
| Percentage change from baseline in F-VASI | Baseline through week 52 | Median % CFB in F-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo |
| Percentage change from baseline in T-VASI | Baseline through week 52 | Median % CFB in T-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo |
| Response based on T-VASI90 | Baseline through week 52 | Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline) |
| Response based on T-VASI100 | Baseline through week 52 | Proportion of participants achieving T-VASI100 (defined as at least 100% improvement in T-VASI from Baseline) |
| Response based on F-VASI50 | Baseline through week 52 | Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline). |
| Response based on F-VASI90 | Baseline through week 52 | Proportion of participants achieving F-VASI90 (defined as at least 50% improvement in F-VASI from Baseline). |
| Response based on F-VASI100 | Baseline through week 52 | Proportion of participants achieving F-VASI100 (defined as at least 100% improvement in F-VASI from Baseline). |
| Patient Global Impression of Severity-Face (PGIS-F) | Weeks 24 and 36 | Proportion of responders based on PGIS-F at 24 and 26 weeks |
| Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Weeks 24 and 36 | Proportion of responders based on PGIS-V at 24 and 36 weeks |
| Patient Global Impression of Change-Face (PGIC-F) | Weeks 24, 36, and 52 | To assess the effect of ritlecitinib compared to placebo on the PGIC-F at 24, 36, and 52 weeks |
| Patient Global Impression of Change- Overall Vitiligo (PGIC-V) | Weeks 24, 36, and 52 | To assess the effect of ritlecitinib compared to placebo on the PGIC-V at 24, 36, and 52 weeks |
| Change from baseline in Dermatology Life Quality Index (DLQI) or Children Dermatology Life Quality Index (CDLQI) | Week 52 | To evaluate the change from baseline in DLQI or CDLQI at week 52 |
| Change from baseline in the Hospital Anxiety and Depression Scale (HADS) | Week 52 | To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52 |
| The proportion of patients achieving absence of depression on HADS depression subscale | Week 52 | Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression) |
| The proportion of patients achieving absence of anxiety on HADS anxiety subscale | Week 52 | Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety) |
Countries
Australia, Bulgaria, Canada, China, Germany, Italy, Japan, Mexico, Poland, South Africa, South Korea, Spain, Turkey (Türkiye), United Kingdom, United States
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed